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Abstract
Inflammation has been implicated as an etiological factor, in several human cancers. Allelic variants of the genes involved in
inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. Besides genetic factors,
environmental factors such as smoking are an important risk factor for prostate cancer. This study aimed to investigate whether
308 G/A single nucleotide polymorphism of tumor necrosis factor-α (TNF-α) gene promoter region was associated with
outcomes of prostate cancer and to analyze the gene environment interaction between 308 G/A TNF polymorphism and
cigarette smoking. A total of 282 patients with prostate cancer (143 smokers, 139 non smoker) and 212 patients with benign
prostatic hyperplasia (105 smokers, 107 non smokers) along with 115 healthy control were enrolled in the study. Urinary
Cotinine and serum TNF and PSA levels were measured using ELISA technique. TNF genotyping was performed using
PCR-RFLP technique. Prostate cancer was significantly associated with TNF G/G genotype and this is accompanied by
elevated plasma TNF, PSA and urinary Cotinine. Cancer smokers showed a high frequency of TNF-α 308 G allele compared
with other patient groups associated with increased TNF levels. Results of this study support the hypothesis that polymorphism
in proinflammatory genes may be important in prostate cancer development and the sequence variants in these inflammatory
genes may interact with environmental modifiers such as cigarette smoking to increase prostate cancer risk.
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INTRODUCTION
Inflammation has been suggested to have a role in
prostate cancer development (De Marzo et al., 2007),
and epidemiologic research on factors such as non-
steroidal anti-inflammatory drug use, obesity, and
prostatitis (MacInnis & Englis, 2006; Hsing &
Chokkalingam, 2006; Mahmud et al., 2004)
provides indirect support for the hypothesis. While
inflammation might promote carcinogenesis
directly, via cellular or DNA damage, it might also
promote carcinogenesis indirectly by increasing cell
turnover and levels of pro-inflammatory factors,
such as tumor necrosis factor-alpha (TNF-α), which
themselves affect cancer risk (Smith et al., 2001;
Palapattu et al., 2005; De Marzo et al., 2007).
Despite the importance of TNF as a mediator of
the inflammatory process (Balkwill, 2002), few
studies have examined associations between TNF
polymorphisms and prostate cancer risk. Results
from existing studies have been mixed, with one
observing significant associations with prostate
cancer risk (Oh et al., 2000) while others did not
(Wu et al., 2004; McCarron et al., 2002; Danforth
et al., 2008).
Tumor necrosis factor-alpha (TNF-α) is an
important inflammatory cytokine that may play a
role in controlling the progression of prostate
cancer. Two common polymorphisms in the TNF-α
gene, -308G/A and -238C/T, have been suggested
to alter the risk for prostate cancer, but the results
have been inconclusive so far (Ma et al., 2014).
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Therefore, the present research was done to study
if there is association between TNF variants and
prostate cancer risk.
METHODS
The current study included adult Egyptian males
with a recent diagnosis of prostate cancer (n=282),
patients with benign prostatic hyperplasia (n=212)
presented at the General surgery department of
Mansoura University Hospital and Mansoura
Oncology Center. Clinical diagnosis of primary
adenocarcinoma of the prostate was histo-
pathologically confirmed after abnormal serum PSA
findings. Patients were selected randomly with a
mean age of 67.4 ± 5.8 years and mean PSA level of
31.6 ± 5.7. Healthy unrelated men (n=115) were
selected as controls; these were recruited from men
attending to our Hospital for unrelated complaints
and with no history of prostate cancer according to
Registry records. They were age matched, clinically
free as regard the urogenital examination and the
mean PSA level was 2.20 ± .07.  The mean of age of
the controls was 59.4 ± 3.7 years.
The patients were classified according to their
smoking history into the following groups: Group
1 include non smoker patients with BPH (n=105),
group 2 include smoker patients with BPH (n=107),
group 3 include non-smoker patients with cancer
(n=139) and group 4 include smoker patients with
cancer (n=143). The control group included 115 age
matched nonsmoker men. Exclusion criteria were:
diabetes mellitus, chronic renal failure, coronary
artery disease, end stage liver disease, positive
serum antinuclear antibody (ANA). Patients and
controls had no history of other malignancy.
All subjects were interviewed by a researcher
and signed their informed consent to participation
in the study, which was approved by the Ethics
Committee of Mansoura University Hospital.
All subjects were instructed to fast for at least
12 hours. A blood sample was withdrawn 3 mls were
delivered to centrifuge tubes containing K2EDTA
(stored as EDTA anti-coagulated blood sample at
-30 C for DNA extraction). Another 5 ml blood
sample was allowed to clot for 15 minutes and
centrifuged at 7000 rpm for 10 minutes for serum
separation to determine: serum PSA, TNF-α. Urine
sample was collected for cotinine estimation.
DNA extraction
Genomic DNA was extracted from EDTA–
anticoagulated peripheral blood leucocytes using
QIA amp DNA Blood Mini Kit supplied by Qiagen
GmbH (Cat. No. 51104, Hiden, Germany) (Schur
et al., 2001). The average DNA concentration
(0.127±0.005μg/μl) was determined from absorbance
at 260 nm (Jenway, Genova Model, UK). All samples
had a 260/280 nm absorbance ratio between 1.6
and 1.79. The integrity of the DNA was checked by
electrophoresis on 0.8% agarose gel stained with
ethidium bromide.
Genotyping of TNF-α -308 gene
TNF-α -308 gene polymorphism study was
carried out by allele-specific polymerase chain
reaction (ASPCR) methods described by Tronchon
et al. (2008) as follow: A TNF-R primer (5'-
TCTCGGTTTCTTCTCCATCG) was used with
either 308-G (5'-ATAGGTTTTGAG GGGCATGG)
or 308-A (5'-ATAGGTTTTGAGGGGCATGA) to
amplify a 184 bp fragment of the TNFα gene, which
includes the polymorphic site at the nucleotide
position -308. The primer pair TNF-F (5'-
GAGTCTCCGGGTCAGAATGA)/TNF-R was used
to amplify a 531 bp TNF gene fragment that was
used as an internal control in the allele-specific
polymerase chain reaction (ASPCR). Primer TNF-F
was also used as a competitor for the TNF-R/A and
TNF-R/G primer pairs to improve the specificity
of the ASPCR assay (Zhu & Clark, 1996). Gene
specific primers were purchased from Biolegio. BV,
PO Box 91, 5600 AB Nijmegen, Netherlands. PCR
was carried out in 50 microliters final reaction
volume using ReadyMix (RED. Taq-PCR Reaction
Mix) (purchased from Sigma Aldrich, Saint Louis,
USA). The following mixture was prepared for
each sample: 25 μl RED-Taq PCR reaction Mix (1X),
1 μl (20 pmole) of forward primer for each allele,
1 μl (20 pmole) of reverse primer, 2 μl (200 ng) of
genomic DNA and 20 μl of double distilled
deionized water. This mix was put in a thin wall
PCR microcentrifuge tube and gently centrifuged
to collect all components to the bottom of the
tube. Then 50 μl mineral oil was added to prevent
evaporation. Amplification was performed in a
Thermal Cycler (Minicycler-PTC-150) using the
following program: After initial heating at 95°C for
10 min, 30 PCR cycles were performed and consisted
of heat denaturation (95°C for 45 s), annealing (for
150 s at 60°C for the TNF primer pair) and extension
(72°C for 45 s). A final extension (72°C for 9 min)
was performed. The resulting PCR product was 184
bp in length for each allele and 531 bp TNF gene
fragment for the internal control. The products were
subjected to agarose gel electrophoresis using 2%
agarose stained with ethidium bromide and
visualized via Light UV Transilluminator (Model
TUV-20, OWI Scientific, Inc. 800 242-5560, France)
and photographed.
Estimation of serum TNF-α level
Quantitative determination of serum TNF-α
level were performed by RayBio Human TNF alpha
ELISA Kit (RayBiotech, Inc. Cat#: ELH-TNFalpha-
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001). This assay employs the quantitative sandwich
ELISA technique which measures TNF-α in 5 hours.
It was performed according to the manufacturer’s
instructions. The absorbance of each sample was
read on plate ELISA reader (Tecan, Sunrise
Absorbance reader) at 450 nm wavelength
(Bonavida, 1991).
Estimation of serum PSA level
Quantitative determination of serum PSA
level were performed by DRG® Total PSA ELISA
(DRG International, Inc., USA. Cat#: EIA-3719).
This assay employs the quantitative sandwich
ELISA technique. It was performed according to the
manufacturer’s instructions, the absorbance of each
sample was read on plate ELISA reader (Tecan, Sunrise
Absorbance reader) at 450 nm wavelength with
blanking at 630nm wavelength (Price et al., 2001).
Estimation of urinary cotinine level
Quantitative determination of urinary cotinine
level was performed by Cotinine ELISA kit (Catalog
No. 40-101-325056, GenWay Biotech, Inc. 6777
Nancy Ridge Drive San Diego, CA 92121). This
assay employs the quantitative solid phase
competitive ELISA technique. It was performed
according to the manufacturers instructions, the
absorbance of each sample was read on plate ELISA
reader (Tecan, Sunrise Absorbance reader) at 450 nm
wavelength (Yeh et al., 2008).
RESULTS
Results showed significant difference in PSA level
among the studied groups. PSA was significantly
higher in cancer patients (32.05 ± 11.51 ng/ml)
than BPH patients (11.76 ± 3.84 ng/ml). It showed
also that smoking has significant effect in BPH
(10.70 ± 2.12 ng/ml) and cancer (56.04 ± 4.39 ng/
ml) patients in comparison to the non smokers
(11.76 ± 3.84 ng/ml and 32.05 ± 11.51 ng/ml
respectively) (Table 2). Table 3 showed significant
difference in TNF level among the studied groups.
TNF was significantly higher in cancer patients
(35.72 ± 6.33 ng/ml) than BPH patients (17.76 ±
4.29 ng/ml). It showed also that smoking has
significant effect in BPH (19.46 ± 5.28 ng/ml) and
cancer (41.56 ± 8.63ng/ml) patients in comparison
to the non smokers (35.72 ± 6.33 ng/ml and 17.76
± 4.29 ng/ml respectively). Table 4 showed
significant difference in cotinine level among the
studied groups. Cotinine was significantly higher in
cancer patients (425.97 ± 125.34 ng/ml) than BPH
patients (376.69 ± 130.97 ng/ml). It showed also
that smoking has significant effect in BPH (1379.6
± 252.64 ng/ml) and cancer (1755.4 ± 230.62 ng/
ml) patients in comparison to the non smokers
(376.69 ± 130.97 ng/ml and 425.97 ± 125.34 ng/ml
respectively). Correlation studies (Table 5 and Graph
1) showed significant correlation between the level
of PSA and TNF (0.832), PSA and cotinine (0.581),
Table 2. Plasma PSA (ng/ml) in the studied groups
Group 4
Cancer smokers
(n=143)
56.04 ± 4.39
t=-128.5  p=0.000
t=-23.24  p=0.000
t=-98.59  p=0.000
Group 3
Cancer
(n=139)
32.05 ± 11.51
t=-27.68  p=0.000
t=-17.34  p=0.000
Group 2
BPH smokers
(n=107)
10.70 ± 2.12
t=-38.01  p=0.000
t=2.49  p=0.014
Group 1
BPH
(n=105)
11.76 ± 3.84
t=-25.58  p=0.000
Control
(n=115)
2.20 ± .07 Mean ± SD
t test Comparison with
the control group
Comparison between
group 1 & 2 and 3 & 4
(Effect of smoking)
Comparison between
group 1 & 3
Comparison between
group 2 & 4
Table 1. Clinical character of patients
Control Group 1 Group 2 Group 3 Group 4BPH BPH smokers Cancer Cancer smokers
No. (n=115) (n=105) (n=107) (n=139) (n=143)
Age 59.4±3.7 60.1±3.7 64.74±3.5 65.33±3.72 67.02±4.88
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Table 3. Plasma TNF (ng/ml) in the studied groups
Group 4
Cancer smokers
(n=143)
41.56 ± 8.63
t=-31.83  p=0.000
t=-6.46  p=0.000
t=-23.4  p=0.000
Group 3
Cancer
(n=139)
35.72 ± 6.33
t=-31.60  p=0.000
t=-25.05  p=0.000
Group 2
BPH smokers
(n=107)
19.46 ± 5.28
t=-9.94  p=0.000
t=-2.58  p=0.011
Group 1
BPH
(n=105)
17.76 ± 4.29
t=-8.18  p=0.000
Control
(n=115)
12.50 ± 5.15 Mean± SD
t test Comparison
with the control group
Comparison between
group 1 & 2 and 3 & 4
(Effect of smoking)
Comparison between
group 1 & 3
Comparison between
group 2 & 4
Table 4. Plasma urinary cotinine (ng/ml) in the studied groups
Group 4
Cancer smokers
(n=143)
1755.4 ± 230.62
t=-62.25  p=0.000
t=-59.92  p=0.000
t=-12.24  p=0.000
Group 3
Cancer
(n=139)
425.97 ± 125.34
t=-7.54  p=0.000
t=-2.98  p=0.003
Group 2
BPH smokers
(n=107)
1379.6 ± 252.64
t=-41.68  p=0.000
t=-36.18  p=0.000
Group 1
BPH
(n=105)
376.69 ± 130.97
t=-3.82  p=0.000
Control
(n=115)
316.77 ± 100.97 Mean± SD
t test Comparison
with the control group
Comparison between
group 1 & 2 and 3 & 4
(Effect of smoking)
Comparison between
group 1 & 3
Comparison between
group 2 & 4
Table 5. Correlation study between the PSA, TNF and cotinine in
studied groups
Cotinine
0.581**
0.000
609
0.463**
0.000
609
1
609
TNF
0.832**
0.000
609
1
609
0.463**
0.000
609
PSA
1
609
0.832**
0.000
609
0.581**
0.000
609
PSA
Pearson correlation
Sig. (2-tailed)
N
TNF
Pearson correlation
Sig. (2-tailed)
N
Cotinine
Pearson correlation
Sig. (2-tailed)
N
** Correlation is significant at the 0.01 level (2-tailed).
PROSTATIC DISEASES: IS IT TOXIC OR GENETIC? 135
TNF and cotinine (0.463). Studying of genotype
distribution of TNF polymorphism showed that
genotype (G / G) is mostly associated with smoker
patients either in BPH (60.7%) and cancer (59.4%)
then non smoker BPH (49.5%) and cancer (48.2%)
patients, which confirm the combined effect of
smoking and genetic precipitation. Studying of
allele frequency of TNF gene showed that G allele
is mostly associated with BPH smokers (90.6%) than
non smokers (80%) and more than cancer patients
either smokers or non smokers (79% and 79.9%
respectively) in Table 6 & Graph 2.
DISCUSSION
Genetic variation likely underlies a significant
proportion of the individual variation in human
susceptibility to toxicants by influencing processes
such as metabolism, oxidative stress, DNA damage
response, and repair. Characterization of this genetic
variability, which is currently not well-understood,
will enable more accurate chemical exposure risk
assessment and the identification of subgroups of
individuals at greater risk of disease resulting from
exposure to toxicants. The main approaches to
Table 6. Genotype distribution and allele frequency of TNF 308 polymorphism in the studied groups
Group 4
Cancer smokers
No (%)
85 (59.4%)
28 (19.6%)
30 (21%)
(n=143)
58 (40.6%)
113 (79%)
Group 3
Cancer
No (%)
67 (48.2%)
44 (31.7%)
28 (20.1%)
(n=139)
72 (51.8%)
111 (79.9%)
Group 2
BPH smokers
No (%)
65 (60.7%)
32 (29.9%)
10 (9.3%)
(n=107)
42 (39.2%)
97 (90.6%)
Group 1
BPH
No (%)
52 (49.5%)
32 (30.5%)
21 (20%)
(n=105)
53 (50.5%)
84 (80%)
Control
No (%)
77 (67%)
25 (21.7%)
13 (11.3%)
(n=115)
38 (33%)
102 (88.7%)
Genotype 1–1 (G / G)
Genotype 2–1 (G / A)
Genotype 2–2 (A / A)
Total No.
A allele
G allele
Graph 1: Correlation study between the PSA, TNF and cotinine in studied groups.
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Graph 2: The genotype distribution and allele frequency of TNF 308 polymorphism in the studied
groups.
Genotype 1-1 (G / G), Genotype 2-1 (G / A), Genotype 2-2 (A / A)
Table 7. A study of PSA, TNF and Conitine in different Genotypes in the studied groups
Cotinine
13
373.40
.03
.01
21
91.90
431.16
47.03
10
.00
952.90
.00
28
48.70
290.25
24.80
30
47.90
1697.35
24.36
TNF
13
16.13
13.37
5.07
21
1.95
20.58
.997
10
.00
21.41
.00
28
.30
39.05
.15
30
16.80
46.50
8.54
PSA
13
3.50
2.17
1.02
21
4.50
11.06
2.30
10
.00
13.23
.00
28
28.00
30.20
.14
30
.20
61.30
.10
Cotinine
25
373.40
.03
.94
32
374.00
401.30
158.72
32
650.50
1485.77
268.08
44
403.00
539.92
90.59
28
66.90
1800.75
34.06
TNF
25
16.13
12.47
5.21
32
5.23
20.167
2.18
32
8.39
22.73
3.70
44
17.78
42.56
3.39
28
4.80
53.70
2.44
PSA
25
3.50
2.18
1.06
32
8.50
16.04
1.78
32
4.00
11.59
1.83
44
36.90
34.30
6.92
28
4.00
53.90
2.04
Cotinine
77
373.40
.03
±.01
52
325.30
339.55
125.65
65
746.50
1392.96
191.41
67
300.60
407.87
101.94
85
829.30
1760.99
295.65
TNF
77
16.13
12.37
±5.20
52
12.30
15.14
4.50
65
13.37
17.56
5.47
67
6.48
29.85
2.35
85
8.20
35.81
2.73
PSA
77
3.50
2.23
±1.10
52
8.80
9.40
2.95
65
6.03
9.87
1.93
67
36.90
31.34
.12
85
10.40
54.89
4.29
No.
Range
Mean
± SD
No.
Range
Mean
± SD
No.
Range
Mean
± SD
No.
Range
Mean
± SD
No.
Range
Mean
± SD
Control
group
BPH
Smokers
BPH
Cancer
Smokers
Cancer
Genotype 2-2 (A / A) Genotype 2-1 (G / A) Genotype 1-1 (G / G)
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identifying gene–environment interactions in
toxicant-mediated disease are candidate gene
association studies and genome-wide association
studies (GWAS), which test for an association of a
subset of genes or pathways or all genes,
respectively, with a toxicant-related phenotypic
outcome (Zhang et al., 2014). TNF-α -308 G/A
polymorphism was associated with increased
hepatocellular carcinoma (HCC) risk in a Han
Chinese population (Feng et al., 2014). Cigarette
smoking had been shown to be a risk factor for
prostate cancer (Hsing et al., 1990, Coughlin et al.,
1996; Plaskon et al., 2003). This study was designed
to investigate whether 308 G/A single nucleotide
polymorphism of tumor necrosis factor-α (TNF-α)
gene promoter region was associated with outcomes
of prostate cancer and to analyze the gene
environment interaction between 308 G/A TNF
polymorphism and cigarette smoking. Results
concluded that prostate cancer is significantly
associated with TNF G/G genotype and this is
accompanied by elevated plasma TNF, PSA and
urinary Cotinine. Cancer smokers showed a high
frequency of TNF-α 308 G allele compared with
other patient groups associated with increased TNF
levels. In contrary Oh et al (2000) observed that the
relative risks of incidence for prostate cancer was
14-fold higher in people with genotype GA at -308
region of TNF-alpha and the genotype GA at -308
of TNF-alpha was related to higher clinical tumour
stage of prostate cancer than genotype G (Oh et al.,
2000). On the other hand, in meta-analysis included
14 studies with 5,757 patients and 6,137 control
subjects for the TNF-α-308G/A polymorphism and
1,967 patients and 2,004 control subjects for the
TNF-α-238C/T polymorphism. A significantly
increased prostate cancer risk was found to be
associated with the TNF-α-308C/T polymorphism in
studies with healthy volunteers. No significant
association was found between the TNF-α-238G/A
polymorphism and prostate cancer risk in the overall
or subgroup analyses Ma et al (2014). Being on
different racial groups may explain the difference in
results. Also, this analysis did not study the effect
of cigarette smoking in those patients. Up to authors
knowledge, this study is the only “until now” that
studied both the effect of smoking and genetic
polymorphism together in both benign and
malignant prostatic disorders. Results of this study
support the hypothesis that polymorphism in
proinflammatory genes may be important in prostate
cancer development and the sequence variants in
these inflammatory genes may interact with
environmental modifiers such as cigarette smoking
to increase prostate cancer risk. Yet, further
prospective studies on large and different ethnic
populations will be necessary to confirm these
findings and elucidate the underlying molecular
effects of cigarette smoking to induce these prostatic
disorders whether directly or through genetic
polymorphism or combined effect.
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